GLP-1 agonists and muscle
3 papers in the library, strongest Preliminary.
Graded Preliminary · A descriptive review without a systematic search or new data; the treatment plan the authors propose has not been tested in a study.
Papers 3
- Weight-Loss Drugs: The Muscle You Lose Matters TooPreliminary2026Journal of Yeungnam medical scienceDrugs such as GLP-1 medicines have changed how doctors treat obesity and type 2 diabetes. They bring meaningful weight loss and better blood sugar. A review from Korea now raises a new question: should weight loss be judged only by how much, or also by what is lost? The authors point to groups who may be most at risk. These include older adults and people with obesity, diabetes, little physical activity, chronic inflammation or low nutritional reserves. If they lose a lot of lean mass, mostly muscle, while slimming down on medication, this may add to age-related muscle loss, frailty, trouble getting around and fractures. Muscle takes up much of the sugar in the blood. Researchers increasingly see faulty mitochondria, the power plants of cells, as a shared mechanism linking insulin resistance, obesity, aging and muscle loss. The authors propose pairing the drugs with strength training, enough protein and micronutrients, and regular checks of body composition and physical function. They also mention experimental treatments aimed at mitochondria. This plan is a proposal from a descriptive review and has not itself been tested in a study.
- Weight-Loss Drugs in Older Adults: The Muscle Question Stays OpenPreliminary2026Current nutrition reportsWeight-loss drugs in the GLP-1 class, such as semaglutide and tirzepatide, reliably help people lose weight. But along with fat, people often lose lean mass, which is mostly muscle. In older adults, muscle loss with age is already a major concern. A review gathered what is known so far. In one analysis that pooled many trials, treated people lost on average 0.86 kilograms more lean mass than comparison groups. In a large tirzepatide trial, fat mass fell by about a third and lean mass by almost 11 percent. There are also some encouraging signs. In single studies, less fat built up inside the muscle. People with type 2 diabetes walked somewhat farther in a six-minute walking test. The authors stress that data on muscle amount, muscle quality and physical performance in older adults are limited and inconsistent. Many trials also included fairly healthy older people. Those with heart or kidney disease were often left out. The authors conclude that treatment should be paired with tailored strength training, enough protein and advice from a dietitian.
- In Mice on Semaglutide, an Enzyme Blocker Aided Muscle RepairPreliminaryn = 82026Proceedings of the National Academy of Sciences of the United States of AmericaWeight-loss shots such as semaglutide bring weight down sharply. But part of what is lost is lean tissue, mostly muscle. In experiments with very overweight mice, an added drug helped injured muscle heal better and regain more strength. It did not noticeably reduce the weight loss. Researchers fed young male mice a very high-fat diet for twelve weeks. The animals then got daily semaglutide, some of them together with a blocker of an enzyme called 15-PGDH. This enzyme breaks down natural signalling molecules and rises after injury and with age. Semaglutide alone made the mice lose about 25 percent of their body weight, and their leg muscles got lighter. After a deliberate muscle injury, the new muscle fibres grew back smaller. With the blocker added, more muscle stem cells divided, the fibres grew larger and the muscles got stronger. Neither drug alone produced this gain in strength. The experiments used only young male mice. Whether people on weight-loss shots would benefit in a similar way was not tested. According to the authors, the blocker has proven safe in early human trials.
How this map is computed
A mark's size is the number of papers we hold on that pairing. It is a count, not a weighting by study design or sample size.
The fill shows the strongest grade in the cell. One Strong paper among four Preliminary ones still fills it dark, so open the cell to see the rest.
Grades and verdicts are assigned by a named person, never by counting.
An empty cell means our library holds no paper on that pairing yet. It is a gap in our library, not proof that nobody has studied it.